Testing tumor DNA markers to predict response to Lu-PSMA in prostate cancer

Trial details

Who runs it

Centre Jean Perrin

Trial code

NCT06600802

Record updated

31 December 2025

Original description

Prostate cancer is the most common cancer in men. Its incidence is rising as the population ages. In the localized stage, the 5-year overall survival rate (OS) is 98%. Metastatic progression and resistance to castration have a negative impact on prognosis. Despite recent advances in management, the 5-year OS is around 30%. Therapeutic advances in this indication have been made mainly by the use of taxanes and second-generation hormone therapy. These treatments have improved OS and progression-free survival (PFS). They are now used as standard therapy.Read full original descriptionShow less

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer (PSMA-PRED)

Prostate cancer is the most common cancer in men. Its incidence is rising as the population ages. In the localized stage, the 5-year overall survival rate (OS) is 98%. Metastatic progression and resistance to castration have a negative impact on prognosis. Despite recent advances in management, the 5-year OS is around 30%. Therapeutic advances in this indication have been made mainly by the use of taxanes and second-generation hormone therapy. These treatments have improved OS and progression-free survival (PFS). They are now used as standard therapy.

More recently, the Phase III VISION trial confirmed the improvement in OS and radiological PFS achieved by treatment with the radioligand 177Lutetium-PSMA-617 (Lu-PSMA) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).

This treatment is currently available in early access in France. Despite encouraging results, 40% of patients will not respond to Lu-PSMA, and there are currently no validated predictive factors. Studies are currently on going, but the identification of biomarkers seems necessary to better stratify risk in these patients.

Numerous tissue prognostic tests based on molecular characteristics or cell proliferation are emerging with this in mind. At present, molecular profiling is not a routine technique for prostate cancer, as it is for other solid cancers. At an early stage, the Decipher® Genomic classification tool has shown prognostic utility independently of therapeutic and clinico-pathological data.

According to recent studies, methylome analysis would enable the subdivision of mCRPCs and could help identify new therapeutic targets.

In the metastatic phase, certain molecular abnormalities involving DNA repair genes are predictive of response to PARP inhibitors.

Molecular analysis (mutations, copy number alterations, gene expression, DNA methylation) could therefore be useful in optimizing the management of mCRPC patients treated with Lu-PSMA.

If reliable molecular abnormalities are identified on tissue, a diagnostic technique based on circulating tumor DNA (ctDNA) analysis will be useful in decision-making for these patients. A biological collection will therefore be created during the course of this study, with a view to using ctDNA analysis in subsequent research.

Inclusion: Male >18 years of age; ECOG ≤ 2; Patient with histologically confirmed of metastatic castration resistant prostatic adenocarcinoma and with tumor biological material available (prostatic biopsies or prostatectomy); Patient who received at least one taxane line and a second generation hormone therapy line; Patient receiving androgen deprivation therapy with serum testosterone < 50 ng/dL or < 1.7 nmol/L or having undergone surgical castration; Progressive mCRPC based based on at least 1 of the following criteria :; Serum or plasma PSA progression defined as 2 consecutive increases in PSA measured at least 1 week prior. The minimal start value is 2.0 ng/mL ; 1,0 ng/mL is the minimal start value if confirmed increase in PSA is the only indication of progress; Soft-tissue progression by RECIST 1.1 criteria; Progression of bone disease : two new lesions ; only the positivity of bone scan defines metastatic bone disease, according to PCWG3 criteria; Patients with at least one metastasis, bone and/or soft tissue and/or visceral, documented by the following methods in the 43 days prior to inclusion :; Bone metastasis (regardless of location) highlighted by bone scan AND/OR; Lymph nodes metastasis, regardless of size and location; if the metastasis are only lymph nodes, the short axis of at least one node should be at least 15 mm AND outside the pelvis ; AND/OR; Visceral metastasis, regardless of size and location; a history of visceral metastasis at any time prior to randomization should be encoded as the presence of visceral metastasis at baseline (i.e., a patient with visceral metastasis prior ADT introduction which are disappeared at baseline will be counted as having visceral metastasis and will be considered to have a high tumor volume during stratification); Patient with Lu-PSMA treatment indication, confirmed by PET 68Ga-PSMA-11. Eligibility for 68Ga-PSMA-11 PET is defined as:; At least one lesion with a binding intensity greater than that of the liver parenchyma (definition of positivity),; All lymph node lesions larger than 25 mm in the short axis must be positive on PSMA PET; All bone metastases with a soft tissue component ≥ 10 mm in the largest diameter must be positive on PSMA-PET; All solid organ metastases (e.g., lung, liver, adrenal glands, etc.) ≥ 10 mm in the largest diameter must be positive on PSMA-PET; Adequate organ function :; Bone marrow reserve :; Absolute neutrophil count ≥ 1.5 x 10\^9/L; Platelets ≥ 100 x 10\^9/L; Hemoglobin ≥ 9 g/dL; Hepatic function :; Total bilirubin ≤ 2 x the upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤ 3 x ULN is permitted; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x ULN OR ≤ 5.0 x ULN for patients with liver metastases; Albumin > 2.5 g/dL; Renal function : Glomerular Filtration Rate (GFR) ≥ 50 mL/min/1.73m2 according to MDRD equation; Obtaining the patient's free and informed consent; Social security scheme or beneficiary.

Exclusion: Continuation of second-generation hormone therapy Patient; Dilation of pyelocalicial cavities not previously supported; Concurrent participation in a therapeutic trial and administration of any investigational agent within 28 days of inclusion; Previous treatment with any of the following in the 6 months prior to inclusion : Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-cyclic irradiation; Previous treatment with radioligands targeting PSMA; Other cancer in the last 3 years likely to change life expectancy or interfere with the assessment of the disease; History of somatic or psychiatric illness/condition that may interfere with study objectives and evaluations; Metastatic tumor tissue as the only material available for prostate cancer diagnosis; Known hypersensitivity to one of the study treatments or its excipients or similar class drugs; Protected adult; Patient unable to understand and comply with study instructions and requirements; ECOG > 2; Obstruction of bladder discharge or uncontrollable and simultaneous urinary incontinence; Symptomatic spinal cord compression or clinical or radiological findings indicating imminent spinal cord compression; Fractured risk of bone damage; Active and symptomatic brain injury; Transfusion or use of bone marrow stimulating agents for the sole purpose of making a participant eligible for inclusion in the study.

ClinicalTrials.gov NCT06600802